Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Nature Communications|July 18, 2024
Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancerHidenori Kitai, Philip H Choi, Yu C Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal CancerNaoko Iida, Mitsuho Imai, Wataru Okamoto, et al.
Cancer Science|October 19, 2020
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancerHiroko Hasegawa, Hiroya Taniguchi, Yoshiaki Nakamura, et al.
Cell Reports. Medicine|August 30, 2025
Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapyKentaro Hirade, Noritaka Tanaka, Taisuke Kajino, et al.
Nature Medicine|November 12, 2021
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trialYoshiaki Nakamura, Wataru Okamoto, Takeshi Kato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2018
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug TargetKyung-A Song, Yasuyuki Hosono, Crystal Turner, et al.
Cancer Discovery|December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitorsAnthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
EMBO Molecular Medicine|March 6, 2019
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancerMohamed I Saad, Sultan Alhayyani, Louise McLeod, et al.
Cancer Cell|December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsRyan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Pageof 8